Day and night locomotor activity effects during administration of (+)-amphetamine

M. T. Martin-Iverson, S. D. Iversen

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Rats were given continuous subcutaneous amphetamine infusions (0, 2, 6, 10 and 20 mg/kg/day) via osmotic minipumps. The effects of these treatments on the locomotor activity of rats were determined over both light and dark phases of a 12-hr light/dark cycle for 336 consecutive hours. It was observed that tolerance to the locomotor stimulant actions of (+)-amphetamine is both dose- and light/dark cycle-dependent. Locomotor stimulation induced by the two highest doses remained high during both day and night throughout the period of treatment, except for the first few days and nights with the highest dose. Tolerance developed only to the effects of the two lower doses, and only during the day. Effects of the low doses on locomotor activity and on circadian patterns of locomotor activity are rughly similar to those previously observed with continuous administration of a selective dopamine D2 agonist. This behavioral similarity suggests that dopamine released by continuous administration of low doses of (+)-amphetamine may be producing its effects via selective actions on DA D2 receptors in vivo.

Original languageEnglish
Pages (from-to)465-471
Number of pages7
JournalPharmacology, Biochemistry and Behavior
Volume34
Issue number3
DOIs
Publication statusPublished - 1 Jan 1989
Externally publishedYes

Fingerprint

Amphetamine
Locomotion
Photoperiod
Rats
Dopamine
Subcutaneous Infusions
Dopamine Agonists
Dosimetry
Light
Therapeutics

Cite this

@article{a3dd7cb401a1438b8bb8b5da538fe15d,
title = "Day and night locomotor activity effects during administration of (+)-amphetamine",
abstract = "Rats were given continuous subcutaneous amphetamine infusions (0, 2, 6, 10 and 20 mg/kg/day) via osmotic minipumps. The effects of these treatments on the locomotor activity of rats were determined over both light and dark phases of a 12-hr light/dark cycle for 336 consecutive hours. It was observed that tolerance to the locomotor stimulant actions of (+)-amphetamine is both dose- and light/dark cycle-dependent. Locomotor stimulation induced by the two highest doses remained high during both day and night throughout the period of treatment, except for the first few days and nights with the highest dose. Tolerance developed only to the effects of the two lower doses, and only during the day. Effects of the low doses on locomotor activity and on circadian patterns of locomotor activity are rughly similar to those previously observed with continuous administration of a selective dopamine D2 agonist. This behavioral similarity suggests that dopamine released by continuous administration of low doses of (+)-amphetamine may be producing its effects via selective actions on DA D2 receptors in vivo.",
keywords = "(+)-Amphetamine, Circadian rhythms, Dopamine D1/D2 receptors, Locomotor activity, Rat, Sensitization, Tolerance",
author = "Martin-Iverson, {M. T.} and Iversen, {S. D.}",
year = "1989",
month = "1",
day = "1",
doi = "10.1016/0091-3057(89)90542-X",
language = "English",
volume = "34",
pages = "465--471",
journal = "Pharmacology Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier",
number = "3",

}

Day and night locomotor activity effects during administration of (+)-amphetamine. / Martin-Iverson, M. T.; Iversen, S. D.

In: Pharmacology, Biochemistry and Behavior, Vol. 34, No. 3, 01.01.1989, p. 465-471.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Day and night locomotor activity effects during administration of (+)-amphetamine

AU - Martin-Iverson, M. T.

AU - Iversen, S. D.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Rats were given continuous subcutaneous amphetamine infusions (0, 2, 6, 10 and 20 mg/kg/day) via osmotic minipumps. The effects of these treatments on the locomotor activity of rats were determined over both light and dark phases of a 12-hr light/dark cycle for 336 consecutive hours. It was observed that tolerance to the locomotor stimulant actions of (+)-amphetamine is both dose- and light/dark cycle-dependent. Locomotor stimulation induced by the two highest doses remained high during both day and night throughout the period of treatment, except for the first few days and nights with the highest dose. Tolerance developed only to the effects of the two lower doses, and only during the day. Effects of the low doses on locomotor activity and on circadian patterns of locomotor activity are rughly similar to those previously observed with continuous administration of a selective dopamine D2 agonist. This behavioral similarity suggests that dopamine released by continuous administration of low doses of (+)-amphetamine may be producing its effects via selective actions on DA D2 receptors in vivo.

AB - Rats were given continuous subcutaneous amphetamine infusions (0, 2, 6, 10 and 20 mg/kg/day) via osmotic minipumps. The effects of these treatments on the locomotor activity of rats were determined over both light and dark phases of a 12-hr light/dark cycle for 336 consecutive hours. It was observed that tolerance to the locomotor stimulant actions of (+)-amphetamine is both dose- and light/dark cycle-dependent. Locomotor stimulation induced by the two highest doses remained high during both day and night throughout the period of treatment, except for the first few days and nights with the highest dose. Tolerance developed only to the effects of the two lower doses, and only during the day. Effects of the low doses on locomotor activity and on circadian patterns of locomotor activity are rughly similar to those previously observed with continuous administration of a selective dopamine D2 agonist. This behavioral similarity suggests that dopamine released by continuous administration of low doses of (+)-amphetamine may be producing its effects via selective actions on DA D2 receptors in vivo.

KW - (+)-Amphetamine

KW - Circadian rhythms

KW - Dopamine D1/D2 receptors

KW - Locomotor activity

KW - Rat

KW - Sensitization

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=0024845242&partnerID=8YFLogxK

U2 - 10.1016/0091-3057(89)90542-X

DO - 10.1016/0091-3057(89)90542-X

M3 - Article

VL - 34

SP - 465

EP - 471

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

SN - 0091-3057

IS - 3

ER -